Search Within

Alexander Edward Drilon

Formats
  1. Meeting Abstract (373)
  2. Journal Article (219)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (631)
  2. Solid Tumor Oncology Division (631)
  3. Thoracic Oncology (631)
  4. Department of Pathology and Laboratory Medicine (205)
  5. GSK Faculty (187)
  6. Human Oncology and Pathogenesis Program (156)

More Groups

People
  1. Marc Ladanyi (121)
  2. Mark Kris (89)
  3. Maria Arcila (82)
  4. David Hyman (78)
  5. Bob Li (65)
  6. Charles Rudin (64)

More People

Years
  1. 2025 (16)
  2. 2024 (61)
  3. 2023 (67)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (84)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (118)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (77)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (631)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 study of oral LOXO 292 in adult patients with advanced solid tumors, including RET-fusion non-small cell lung cancer, medullary thyroid cancer and other tumors with increased RET activity
    Meeting Abstract

    Drilon, A. E.; Bauer, T. M.; Subbiah, V.; Cabanillas, M.; Lahkani, N.; Wirth, L.; Oxnard, G.; Smith, S.; Eary, T.; Cruickshank, S.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC
    Meeting Abstract

    Drilon, A. E.; Liu, S.; Doebele, R.; Rodriguez, C.; Fakih, M.; Reckamp, K. L.; Bazhenova, L.; Cho, B. C.; Kowack, E.; Oliver, J.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Pan-TRK immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions
    Journal Article

    Hechtman, J. F.; Benayed, R.; Hyman, D. M.; Drilon, A.; Zehir, A.; Frosina, D.; Arcila, M. E.; Dogan, S.; Klimstra, D. S.; Ladanyi, M.; more...
    American Journal of Surgical Pathology (2017)

    Fulltext@MSK | Save
  • A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors
    Journal Article

    Drilon, A.; Nagasubramanian, R.; Blake, J. F.; Ku, N.; Tuch, B. B.; Ebata, K.; Smith, S.; Lauriault, V.; Kolakowski, G. R.; Brandhuber, B. J.; more...
    Cancer Discovery (2017)

    Fulltext@MSK | Save
  • Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target
    Journal Article

    Cook, P. J.; Thomas, R.; Kannan, R.; de Leon, E. S.; Drilon, A.; Rosenblum, M. K.; Scaltriti, M.; Benezra, R.; Ventura, A.
    Nature Communications (2017)

    Fulltext@MSK | Save
  • RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Filippo, P.; Alexa, S.; Jeeyun, L.; Alexander, D.; Jason, C.; Vi, C.; Giovanni, F.; Federica, M.; Daniele, R.; Tae, K. S.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: Time to move on to better biomarkers?
    Journal Article

    Santini, F. C.; Kunte, S.; Drilon, A.
    Translational Lung Cancer Research (2017)

    Fulltext@MSK | Save
  • Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions
    Meeting Abstract

    Rangaraju, S.; Farago, A.; Heym, K. M.; Ahn, M.; Drilon, A.; Potts, S.; Hornby, Z.; Multani, P.; Li, G.
    Neuro-Oncology (2017)

    Fulltext@MSK | Save
  • Targeting RET-rearranged lung cancers with multikinase inhibitors
    Journal Article

    Sabari, J. K.; Siau, E. D.; Drilon, A.
    Oncoscience (2017)

    Fulltext@MSK | Save
  • Antitumor activity of RXDX-105 in multiple cancer types with RET rearrangements or mutations
    Journal Article

    Li, G. G.; Somwar, R.; Joseph, J.; Smith, R. S.; Hayashi, T.; Martin, L.; Franovic, A.; Schairer, A.; Martin, E.; Riely, G. J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save